The panel examine toxicity and morbidity considerations for the use of hedgehog pathway inhibitors in BCC. This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; ...
John Hood, PhD, cofounder and CEO of Endeavor BioMedicines, explains the potential advantages of ENV-101 during a time with very few treatments for idiopathic pulmonary fibrosis (IPF). There's ...
A discovery with major implications for cancer treatment has been made by a team of researchers from Rensselaer Polytechnic Institute (RPI), the University of Nebraska Medical Center (UNMC), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results